#United States #New York #Pomerantz LLP #Soleno Therapeutics #SLNO

Investigation Overview

Pomerantz LLP, a renowned law firm based in New York, is currently investigating possible claims on behalf of investors associated with Soleno Therapeutics, Inc. (NASDAQ: SLNO). This scrutiny arises after a substantive report by Scorpion Capital raised significant concerns regarding the company's only product, Vykat XR.

Background on Soleno Therapeutics

Founded to develop innovative therapies for rare diseases, Soleno Therapeutics has been under the spotlight due to its focus on pediatric treatment options. However, recent developments prompted adverse reactions from the market and allegations concerning its business practices and product safety.

The Scorpion Capital Report

On August 15, 2025, Scorpion Capital published a report labeling Vykat XR as overpriced and suggesting that it bears potential risks for children. The report has drawn attention as it directly called into question the safety and efficacy of the medication, prompting a swift response from investors and stakeholders alike. Post-report, Soleno's stock price witnessed a steep decline of $5.73, equivalent to a 7.41% drop, closing at $71.63. This dramatic shift indicates mounting concerns regarding investor confidence and the possible implications of the report's findings on Soleno's market position.

Legal Implications

Pomerantz LLP's investigation focuses on whether Soleno Therapeutics and certain officers or directors engaged in securities fraud or other illicit business practices prior to and following the release of Scorpion's report. Investors are advised to be vigilant and consider their options regarding possible losses incurred from the company's declining share value. To this end, they are encouraged to contact Pomerantz LLP for more information on participating in potential class action claims.

Pomerantz LLP: A Leader in Securities Litigation

With over 85 years of experience, Pomerantz LLP has established itself as a leader in corporate and securities litigation. Founded by Abraham L. Pomerantz, known as the dean of the class action bar, the firm has a long-standing tradition of advocating for the rights of investors affected by securities fraud and corporate misconduct. In their history, they have recovered numerous multimillion-dollar awards for affected shareholders, reinforcing their commitment to holding corporations accountable.

Next Steps for Investors

Investors seeking further information about their rights and potential claims against Soleno Therapeutics are advised to reach out to Danielle Peyton at Pomerantz LLP. They can contact her via email at [email protected] or by phone at 646-581-9980, ext. 7980.

Conclusion

The ongoing investigation by Pomerantz LLP highlights the importance of investor vigilance in the face of corporate practices that may affect share value and market trust. As Soleno Therapeutics navigates these challenges, the implications of the Scorpion Capital report will likely play a critical role in shaping the company's future and restoring investor confidence.